Chemotherapy resistance and risk stratification in gestational trophoblastic neoplasia: A systematic review and network meta‐analysis
5 affiliations
- 1Center for Evidence‐Based Medicine and Clinical Research Taihe Hospital, Hubei University of Medicine Shiyan Hubei Province China
- 2Department of Radiology Shengjing Hospital of China Medical University Shenyang Liaoning Province China
- 3Department of Obstetrics and Gynecology Taihe Hospital, Hubei University of Medicine Shiyan Hubei Province China
- 4Hubei Key Laboratory of Embryonic Stem Cell Research Taihe Hospital, Hubei University of Medicine Shiyan Hubei Province China
- 5Department of Histology and Embryology, School of Basic Medical Sciences Hubei University of Medicine Shiyan Hubei Province China
Abstract
Introduction: Gestational trophoblastic neoplasia (GTN) is highly chemosensitive, but resistance to initial chemotherapy remains clinically important despite International Federation of Gynecology and Obstetrics (FIGO) score‐guided management. Evidence on pretreatment predictors of chemoresistance and comparative chemoresistance across chemotherapy regimens remains limited. This study aimed to estimate the burden of chemoresistance, identify pretreatment risk factors, and compare chemotherapy regimens using pairwise and network meta‐analysis to inform risk stratification and future treatment optimization.
Material and Methods: Eight databases (PubMed, Embase, Cochrane Library, Web of Science, CBM, CNKI, VIP, and Wanfang) were searched from inception to August 26, 2025. Two reviewers independently screened records, extracted data, and assessed risk of bias using the RTI Item Bank. Pairwise meta‐analyses were used to pool the chemoresistance rate and evaluate associations between pretreatment factors and chemoresistance. A frequentist random‐effects network meta‐analysis was performed to compare chemoresistance risks across chemotherapy regimens, with ranking probabilities summarized using the surface under the cumulative ranking curve (SUCRA).
Results: Fifty‐three studies involving 7585 patients and 1997 resistant cases yielded a pooled chemoresistance rate of 23.8% (95% CI: 20.7%–27.1%; p < 0.001). Higher chemoresistance was associated with choriocarcinoma, antecedent full‐term pregnancy, a high FIGO score, higher pretreatment β‐hCG, especially > 105 IU/L, longer intervals from antecedent pregnancy (7–12 and > 12 months), greater tumor burden (tumor diameter ≥5 cm, presence of metastasis, and ≥ 5 metastatic lesions), FIGO stage II or IV disease, and first‐line single‐agent chemotherapy. In exploratory ranking analyses, methotrexate (MTX) and fluorouracil (FU) tended to rank higher for predicted chemoresistance, whereas etoposide (ETP) and FU + actinomycin D + etoposide + vincristine (FAEV) tended to rank lower.
Conclusions: Approximately one quarter of patients with GTN develop chemoresistance. Pretreatment factors, including clinicopathologic type when available, tumor burden, FIGO score and stage, antecedent pregnancy characteristics, and pretreatment β‐hCG level, may help identify patients at higher risk of chemoresistance. Exploratory regimen‐ranking analyses suggested lower predicted chemoresistance for etoposide‐containing regimens, particularly FAEV; however, these findings require prospective validation before they can inform treatment selection.
Related
- Epidemiology, treatment patterns, and outcomes in gestational trophoblastic neoplasia: a systematic review
- Gestational Trophoblastic Disease and Its Outcome at Shri Maharaja Gulab Singh Hospital, Jammu, India: A Retrospective Data Analysis
- Report of two patients with variants in FOXL2 and KASH5 and review of gestational trophoblastic neoplasia after recurrent moles
- Gestational trophoblastic neoplasia in the Western Brazilian Amazon: Patient characteristics and impact of referral center restructuring
- Laparoscopic and Robot-Assisted Surgery for Gestational Trophoblastic Disease: A Scoping Review of Patient Selection and Intraoperative Precautions.
BibTeX
@article{xue2026chemotherapy,
title = {{Chemotherapy resistance and risk stratification in gestational trophoblastic neoplasia: A systematic review and network meta‐analysis}},
author = {Ying‐Ying Xue and Xin‐Yue Yang and Fang‐Yu Chen and Hui‐Ting Yang and Chao Zhang and Jin‐Zhu Yan and Shi‐Shi Wu and Long Wang},
journal = {Acta Obstetricia et Gynecologica Scandinavica},
year = {2026},
month = aug,
doi = {10.1111/aogs.70333},
url = {https://doi.org/10.1111/aogs.70333},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Chemotherapy resistance and risk stratification in gestational trophoblastic neoplasia: A systematic review and network meta‐analysis
AU - Ying‐Ying Xue
AU - Xin‐Yue Yang
AU - Fang‐Yu Chen
AU - Hui‐Ting Yang
AU - Chao Zhang
AU - Jin‐Zhu Yan
AU - Shi‐Shi Wu
AU - Long Wang
PY - 2026
DA - 2026/08/18
JO - Acta Obstetricia et Gynecologica Scandinavica
DO - 10.1111/aogs.70333
UR - https://doi.org/10.1111/aogs.70333
AB - Introduction: Gestational trophoblastic neoplasia (GTN) is highly chemosensitive, but resistance to initial chemotherapy remains clinically important despite International Federation of Gynecology and Obstetrics (FIGO) score‐guided management. Evidence on pretreatment predictors of chemoresistance and comparative chemoresistance across chemotherapy regimens remains limited. This study aimed to estimate the burden of chemoresistance, identify pretreatment risk factors, and compare chemotherapy regimens using pairwise and network meta‐analysis to inform risk stratification and future treatment optimization. Material and Methods: Eight databases (PubMed, Embase, Cochrane Library, Web of Science, CBM, CNKI, VIP, and Wanfang) were searched from inception to August 26, 2025. Two reviewers independently screened records, extracted data, and assessed risk of bias using the RTI Item Bank. Pairwise meta‐analyses were used to pool the chemoresistance rate and evaluate associations between pretreatment factors and chemoresistance. A frequentist random‐effects network meta‐analysis was performed to compare chemoresistance risks across chemotherapy regimens, with ranking probabilities summarized using the surface under the cumulative ranking curve (SUCRA). Results: Fifty‐three studies involving 7585 patients and 1997 resistant cases yielded a pooled chemoresistance rate of 23.8% (95% CI: 20.7%–27.1%; p < 0.001). Higher chemoresistance was associated with choriocarcinoma, antecedent full‐term pregnancy, a high FIGO score, higher pretreatment β‐hCG, especially > 105 IU/L, longer intervals from antecedent pregnancy (7–12 and > 12 months), greater tumor burden (tumor diameter ≥5 cm, presence of metastasis, and ≥ 5 metastatic lesions), FIGO stage II or IV disease, and first‐line single‐agent chemotherapy. In exploratory ranking analyses, methotrexate (MTX) and fluorouracil (FU) tended to rank higher for predicted chemoresistance, whereas etoposide (ETP) and FU + actinomycin D + etoposide + vincristine (FAEV) tended to rank lower. Conclusions: Approximately one quarter of patients with GTN develop chemoresistance. Pretreatment factors, including clinicopathologic type when available, tumor burden, FIGO score and stage, antecedent pregnancy characteristics, and pretreatment β‐hCG level, may help identify patients at higher risk of chemoresistance. Exploratory regimen‐ranking analyses suggested lower predicted chemoresistance for etoposide‐containing regimens, particularly FAEV; however, these findings require prospective validation before they can inform treatment selection.
SN - 0001-6349
SN - 1600-0412
ER -